Chloroquine’s EUA, new FDA coronavirus treatment accelerator, No Penalties for Zolgensma

Pink Sheet reporters and editors discuss the lingering questions surrounding the emergency use authorization of chloroquine and the FDA’s new program to speed therapeutic development for coronavirus, as well as break down the agency decision to not sanction Novartis over its Zolgensma data integrity problems.